Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy

2001 ◽  
Vol 218 (8) ◽  
pp. 1275-1280 ◽  
Author(s):  
Kaitkanoke Sirinarumitr ◽  
Shirley D. Johnston ◽  
Margaret V. Root Kustritz ◽  
Gary R. Johnston ◽  
Dipak K. Sarkar ◽  
...  
Keyword(s):  
Semen Quality ◽  
Prostate Gland ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy

scholarly journals Intraurethral Catheter: Alternative Management for Urinary Retention in Patients With Benign Prostatic Hypertrophy

1995 ◽  
Vol 2 (2) ◽  
pp. 113-117
Author(s):  
Sulabha Punekar ◽  
Prem A. Ramkrishnan ◽  
Anand R. Kelkar ◽  
Jaydeep A. Date ◽  
Vasudeo R. Ridhorkar
Keyword(s):  
Urinary Retention ◽  
Peak Flow ◽  
Prostate Gland ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Fluoroscopic Control ◽  
Calculus Formation ◽  
Clinically Significant

A polyurethane intraurethral catheter (IUC) was used in 27 patients with benign prostatic hypertrophy who were unfit for surgery, or were awaiting surgery. All of them had previously had a periurethral catheter inserted. The IUC was inserted with a cystoscope under fluoroscopic control. Spontaneous voiding through the IUC resumed in 25 patients (93%) in the immediate postprocedure period. At the end of 6 months follow-up, the peak flow rates and the residual volumes estimated in 22 patients were satisfactory. Immediate complications included incontinence due to distal displacement in 2 patients and hematuria in one patient; long-term complications included mild encrustation of the IUC in 2 patients and calculus formation on the IUC in 1 patient. None of the patients had clinically significant urinary tract infection. The presence of the IUC did not compromise the subsequent transurethral resection of the prostate gland. We recommend the use of an IUC for up to 6 months in patients with urinary retention who are awaiting surgery or are unfit for surgery as an alternative to an indwelling urethral catheter.

Interaction between prolactin and zinc in the human prostate gland

1984 ◽  
Vol 102 (1) ◽  
pp. 73-76 ◽  
Author(s):  
A. Leake ◽  
G. D. Chisholm ◽  
F. K. Habib
Keyword(s):  
Specific Binding ◽  
Prostate Gland ◽  
Benign Prostatic Hypertrophy ◽  
Peptide Hormone ◽  
Prostatic Hypertrophy ◽  
Human Prostate ◽  
Binding Properties ◽  
Competitive Mechanism ◽  
Human Prolactin

ABSTRACT The interaction between prolactin and zinc was examined in vitro in the human prostate gland. The results indicated that prolactin did not modulate the acute uptake of zinc into benign prostatic hypertrophy tissue whereas zinc, in contrast, increased the uptake of prolactin into the prostate gland. Our study further showed that the augmented uptake of prolactin by zinc was partly due to an increase in the non-specific binding properties of the peptide hormone. We were also able to demonstrate that the specific binding of 125I-labelled human prolactin to the receptor was reduced in the presence of zinc by a competitive mechanism. J. Endocr. (1984) 102, 73–76

Local Hyperthermia of the Prostate Gland for the Treatment of Benign Prostatic Hypertrophy and Urinary Retention

1990 ◽  
Vol 65 (2) ◽  
pp. 201-203 ◽  
Author(s):  
A. LINDNER ◽  
Z. BRAF ◽  
A. LEV ◽  
J. GOLOMB ◽  
Z. LEIB ◽  
...  
Keyword(s):  
Urinary Retention ◽  
Prostate Gland ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Local Hyperthermia

Laser treatment of benign prostatic hypertrophy

1996 ◽  
Vol 63 (1) ◽  
pp. 77-80
Author(s):  
S. Guazzieri ◽  
W. Cecchetti ◽  
M. Meneguolo ◽  
G. D'incà ◽  
R. Bertoldin
Keyword(s):  
Laser Treatment ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Laser Source ◽  
Experimental Procedure ◽  
The Usa ◽  
Side Emission ◽  
Pace Maker ◽  
Stable Laser ◽  
Good Flow

— Laser treatment of benign prostatic hypertrophy (BPH) has gradually become more widespread over the last few years. In the USA it is considered an alternative to endoscopic resection as far as insurance payments are concerned. Different methods are used but the most common and suitable one for urologists is the removal and coagulation of the prostatic tissue under visual control (VLAP or ELAP). The Authors report their personal experience in this type of treatment where good results are due to: 1) combination of a powerful, stable laser source 2) durable side-emission contact fibre 3) laser resector, which also in the absence of epicystostomy maintains a good flow during the operation. However, “laser resection” should still be considered an experimental procedure to be used for randomised protocols or on selected patients (high risk of bleeding, Jehovah's witnesses, carriers of pace-maker, etc.).

SECRETION OF DIHYDROTESTOSTERONE BY HUMAN PROSTATE IN BENIGN PROSTATIC HYPERTROPHY

1974 ◽  
Vol 77 (2) ◽  
pp. 401-407 ◽  
Author(s):  
J. A. Mahoudeau ◽  
A. Delassalle ◽  
H. Bricaire
Keyword(s):  
Plasma Levels ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Human Prostate ◽  
Control Subjects ◽  
Peripheral Plasma ◽  
Significant Difference ◽  
Before And After ◽  
The Mean ◽  
And Control

ABSTRACT Plasma levels of testosterone (T) and 5α-dihydrotestosterone (DHT) were determined by radioimmunoassay in 29 patients with benign prostatic hypertrophy (BPH) and in 56 control men of various ages. No significant difference was found in T, DHT nor DHT/T ratio between BPH and control subjects of similar age. Plasma DHT was higher in the prostatic than in the peripheral veins in 8/9 patients with BPH during laparotomy, indicating a prostatic secretion of DHT. No difference in the mean T nor the mean DHT was found in peripheral plasma before and after adenomectomy.

Sign in / Sign up

Export Citation Format

Share Document